#Mifepristone

#Mifepristone

The anti-abortion Slenderman that is Sen. Josh Hawley (R-Mo.) has spent much of his political career trying to dismantle abortion rights. But he's spent the past year obsessively amplifying a bogus "study" from the far-right Ethics and Public Policy Center (which is listed as an advisor under Project 2025), which published false findings about the abortion pill, mifepristone, having "adverse effects" on women.

In the summer of 2021, a small group of about 12 individuals, including some health care workers, elected officials, and local community activists, in the deep-red state of Wyoming-which didn't have a single abortion clinic at the time-began planning to open a new clinic in the college town of Casper. This was at the same time that most abortion clinics in red states, seeing the writing on the wall, had begun planning to close

In 2026, the biggest battles over abortion will not be at the polls. There will be a few contested measures on state ballots. Next year, Nevada's government will ask residents to approve constitutional protection for abortion rights for the second time, as required by state law. The same measure passed in 2024 with just over 64% of the vote. Virginians will likely see a similar ballot initiative.

At the end of August, Texas and Florida's attorneys general asked to join GOP attorneys general from Missouri, Idaho, and Kansas in a yearslong lawsuit targeting mifepristone - breathing new life into the litigation attacking the most widely used method of abortion in the United States.

extra-territorial mailing of abortion drugs is illegal under state law.

The abortion pill mifepristone has been proven safe by millions of Americans over 25 years, and its restrictions threaten access particularly for vulnerable populations.

The Trump administration's request to dismiss the mifepristone lawsuit appears as a defense of the drug, despite the president's history of rolling back abortion rights.

Our data shows that chemical abortion poses greater risks to women in real-world clinical use than revealed in the clinical trials of mifepristone and that the rate of serious adverse events from the chemical abortion regimen continues to grow in recent years.